Exclusive Summary

• Potential Best-in-Class (BIC) APP-siRNA: Preclinical data shows superior target knockdown in key brain regions (hippocampus) compared to its direct competitor (Mivelsiran), indicating greater potency.
• Significant Safety and Convenience Advantages: Unlike approved Aβ antibodies, UB643 is expected to inherently avoid the serious safety risk of ARIA (Amyloid-Related Imaging Abnormalities), and its potential for yearly dosing would dramatically improve patient compliance.
• Innovative Strategic Value for Combination Therapy: As an upstream inhibitor, UB643 shows potential for synergistic effects when combined with Aβ antibodies, offering a strategic option for partners to build a next-generation AD combo therapy.
• Expansion to Untapped Indications: Beyond Alzheimer's Disease, the asset has potential for development in Cerebral Amyloid Angiopathy (cAA), an indication with no currently approved drugs.

Asset Materials

Contact Us for Full Materials